Archive

Dive into a collection of past posts and rediscover timeless content.

2 Stocks to Avoid as Crypto Momentum Wanes

Dec 22, 2025

•

3 min read

2 Stocks to Avoid as Crypto Momentum Wanes

With Bitcoin losing steam and regulatory clarity still off in the distance, crypto-linked names like SharpLink Gaming and TeraWulf face rising valuation and debt risks. Avoid these stocks until market momentum or clearer rules return.

Is Tesla Overvalued? 2 Reasons It Might Be a Bargain

Dec 21, 2025

•

3 min read

Is Tesla Overvalued? 2 Reasons It Might Be a Bargain

A triple‐digit P/E may look frothy, but a momentum-fueled breakout and strong analyst price targets suggest this rally could have more upside.

Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500

Dec 20, 2025

•

3 min read

Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500

Shares plunged 20% after earnings, but several Wall Street analysts raised targets to $500, implying more than 50% upside. Their bullish calls hinge on Broadcom’s AI-driven cash flow and a market-analyst disconnect over the sell-off.

Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?

Dec 19, 2025

•

1 min read

Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?

A possible move to reschedule marijuana to Schedule III could lift banking, tax and institutional barriers — unlocking capital that might fuel a major reversal. Still, support is tepid and retail-driven volatility means gains will depend on concrete policy and market catalysts.

Paramount Threw a Wrench in Netflix's Bid to Acquire Warner Bros.

Dec 18, 2025

•

3 min read

Paramount Threw a Wrench in Netflix's Bid to Acquire Warner Bros.

Paramount Skydance’s $30 all‐cash hostile bid upends Netflix’s cash‐and‐stock agreement, reigniting a potential bidding war. Antitrust scrutiny and shareholder votes are now likely to decide the winner.

Pfizer Adds to Its Big Bet on Weight Loss Drugs

Dec 17, 2025

•

3 min read

Pfizer Adds to Its Big Bet on Weight Loss Drugs

With a $2.1 billion licensing deal and a recent $10 billion buyout, Pfizer is doubling down on GLP‐1 pills and combo therapies to recoup waning COVID‐vaccine revenue.

3 Underrated Robotics Stocks Poised for Huge Gains

Dec 16, 2025

•

3 min read

3 Underrated Robotics Stocks Poised for Huge Gains

Small-cap robotics plays — Stereotaxis, Knightscope, and PROCEPT — with FDA approvals, new product rollouts, and improving production that could trigger significant upside. High-risk, under-the-radar opportunities for investors willing to look beyond the AI giants.

2 Small-Cap Biotechs That Could Reward Patient Investors

Dec 15, 2025

•

3 min read

2 Small-Cap Biotechs That Could Reward Patient Investors

Two speculative micro-cap plays — Mainz Biomed’s commercial cancer screen and NanoViricides’ novel antiviral platform — that could deliver outsized returns for investors willing to weather high risk and long timelines.

Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside

Dec 14, 2025

•

3 min read

Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside

Modest post-earnings pop leaves Adobe trading on muted growth assumptions, creating roughly 20% upside if its AI push reaccelerates ARR. Still, mounting competition and potential margin pressure could temper the rally.

Broadcom Slips Post-Earnings Even as AI Demand Goes Parabolic

Dec 13, 2025

•

3 min read

Broadcom Slips Post-Earnings Even as AI Demand Goes Parabolic

Blistering AI demand and a forecast for AI chip revenue to double couldn't stop a post‐earnings selloff as investors worried about margin pressure and a smaller‐than‐expected backlog.

Archive

Dive into a collection of past posts and rediscover timeless content.

2 Stocks to Avoid as Crypto Momentum Wanes

Is Tesla Overvalued? 2 Reasons It Might Be a Bargain

Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500

Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?

Paramount Threw a Wrench in Netflix's Bid to Acquire Warner Bros.

Pfizer Adds to Its Big Bet on Weight Loss Drugs

3 Underrated Robotics Stocks Poised for Huge Gains

2 Small-Cap Biotechs That Could Reward Patient Investors

Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside

Broadcom Slips Post-Earnings Even as AI Demand Goes Parabolic

The Markets Daily